Response to treatment in patients with multiple myeloma: PET/CT imaging with [68Ga]Ga-Pentixafor

Summary description of the study

In the presence of multiple myeloma, the standard examination at the time of diagnosis consists of performing PET/CT imaging with the FDG molecule and monitoring through blood parameters. Unfortunately, the FDG tracer can have some disadvantages, such as not visualizing certain lesions in the bones. Monitoring the disease through blood parameters can also provide false reassurance in cases of locally active disease. The aim of this study is to perform PET/CT imaging with a molecule called [68Ga]Ga-PentixaFor, in order to measure the activity of this disease through imaging, compare this activity to what can be measured in the blood, and evaluate the advantages of [68Ga]Ga-PentixaFor compared to PET/CT using FDG. The goal is to perform imaging before the initiation of myeloma treatment (or before a new treatment in case of relapse), and then after 8 to 12 weeks of treatment for disease monitoring.

(BASEC)

Intervention under investigation

2 PET/CT scans with the research molecule [68Ga]Ga-PentixaFor (investigation #1 at the start and then investigation #2 at 8-12 weeks). This examination lasts about 15 – 20 minutes. In total, the patient spends about 2 hours in the nuclear medicine department.

(BASEC)

Disease under investigation

Multiple myeloma

(BASEC)

Sponsor

Prof. Dr. Niklaus Schaefer, Nuclear Medicine Service, CHUV, Lausanne

(BASEC)

Name of the authorising ethics committee (for multicentre studies, only the lead committee)

Ethics Committee Vaud

(BASEC)

Date of authorisation

24.02.2025

(BASEC)

Results of the trial